About
Monoclonal Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
415
By Phase
PHASE1/PHASE2: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06827613Lead Sponsor
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
50 participants
Started: Mar 24, 2025 · Completed: Jan 31, 2028
NCT05592626Lead Sponsor
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
365 participants
Started: Jan 4, 2023 · Completed: Oct 31, 2026
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...